On 26 November 2010, orphan designation (EU/3/10/814) was granted by the European Commission to Baxter Innovations GmbH, Austria, for recombinant human von Willebrand factor for the treatment of von Willebrand disease.
In May 2015, Baxter Innovations GmbH changed name to Baxalta Innovations GmbH.
Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in July 2018 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.
Recombinant human von Willebrand factor
|Disease / condition||
treatment of von Willebrand disease
|Date of decision||
|Orphan decision number||
Review of designation
The Committee for Orphan Medicinal Products reviewed the orphan designation of Veyvondi at the time of marketing authorisation.
The sponsor formally requested the withdrawal of the orphan designation prior to the Committee's final opinion. More information is available in the withdrawal assessment report - orphan maintenance .
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.